Search results
2 paź 2023 · Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease.
15 lis 2023 · Monoclonal antibodies that target different amyloid-beta (Aβ) protein species in persons with Alzheimer’s disease have been developed, but phase 2 and phase 3 clinical trials of these drugs...
24 kwi 2024 · Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity.
Tematy dnia
The National Institute on Aging (NIA) is currently supporting 461 active clinical trials on Alzheimer’s disease and related dementias (AD/ADRD). These trials reflect diverse drug and mechanistic targets, as well as diversity in the stages of AD/ADRD they address.
13 lut 2023 · Eric M. Reiman. Researchers have long sought a treatment for Alzheimer’s disease that could target the biological underpinnings of the condition and slow cognitive decline and its disabling...
17 lip 2023 · Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer’s disease have had mixed results. Methods. We tested solanezumab, which targets monomeric...
25 maj 2023 · There are currently 187 trials assessing 141 drugs for the treatment of Alzheimer's disease (AD). Drugs in the AD pipeline address a variety of pathological processes. More than 57,000 participants will be required to populate all currently registered trials.
